Movatterモバイル変換


[0]ホーム

URL:


SG11201804098TA - Purinones as ubiquitin-specific protease 1 inhibitors - Google Patents

Purinones as ubiquitin-specific protease 1 inhibitors

Info

Publication number
SG11201804098TA
SG11201804098TASG11201804098TASG11201804098TASG11201804098TASG 11201804098T ASG11201804098T ASG 11201804098TASG 11201804098T ASG11201804098T ASG 11201804098TASG 11201804098T ASG11201804098T ASG 11201804098TASG 11201804098T ASG11201804098T ASG 11201804098TA
Authority
SG
Singapore
Prior art keywords
massachusetts
international
street
inhibitors
pct
Prior art date
Application number
SG11201804098TA
Inventor
Alexandre Joseph Buckmelter
Stephanos Ioannidis
Bruce Follows
Gary Gustafson
Minghua Wang
Justin A Caravella
Zhongguo Wang
Edward L Fritzen
Jian Lin
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics IncfiledCriticalForma Therapeutics Inc
Publication of SG11201804098TApublicationCriticalpatent/SG11201804098TA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau ... .51d > (43) International Publication Date .. ....7r ,,,,,01 26 May 2017(26.05.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/087837 Publication Number Al (51) International Patent Classification: (74) Agents: FARMER, J.Dean et al.; Cooley LLP, 1299 C07D 473/00 (2006.01) A61P 35/00 (2006.01) Pennsylvania Avenue, Suite 700, Washington, District of A61K 31/522 (2006.01) Columbia 20004 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2016/062837 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 18 November 2016 (18.11.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (26) Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (30) Priority Data: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/258,162 20 November 2015 (20.11.2015) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (71) Applicant: FORMA THERAPEUTICS, INC. [US/US]; ZW. 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: BUCKMELTER, Alexandre Joseph; 139 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Prospect Street #5, Acton, Massachusetts 01720 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, IOANNIDIS, Stephanos; 8 Penobscot Road, Natick, Mas- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, sachusetts 01760 (US). FOLLOWS, Bruce; 25 Baldwin DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Hill Road, Littleton, Massachusetts 01460 (US). GUST- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, AFSON, Gary; 33 Ridgecrest Drive, Ridgefield, Connecti- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, cut (US). 06877 WANG, Minghua; 30 Squirrel Hill, Ac- GW, KM, ML, MR, NE, SN, TD, TG). ton, Massachusetts 01720 (US). CARAVELLA, Justin Declarations Rule 4.17: under A.; 121 Sciarappa Street #3, Cambridge, Massachusetts 02141 (US). WANG, Zhongguo; 19 Earl Street, Lexing- — as to applicant's entitlement to apply for and be granted a ton, Massachusetts 02421 (US). FRITZEN, Edward L.; 2 patent (Rule 4.170) Peach Tree Lane, Niantic, Connecticut 06357 (US). LIN, Published: Jian; 3 Beechnut Street, Acton, Massachusetts 01720 — with international search report (Art 21(3)) (US). (54) Title: PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS Ri \ N 0 — < Xi ,... R X2 1-1 .4t it--- M ot o h o O t-- Il (57) : The application relates R to inhibitors R3 n of USP1 useful in the „t or si R4 treatment I %, ... \" . X .. t. 3 X4 of cancers, and (I), other USP1 associated diseases O and disorders, having the Formula: (I), where RI, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein. ei 0
SG11201804098TA2015-11-202016-11-18Purinones as ubiquitin-specific protease 1 inhibitorsSG11201804098TA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US201562258162P2015-11-202015-11-20
PCT/US2016/062837WO2017087837A1 (en)2015-11-202016-11-18Purinones as ubiquitin-specific protease 1 inhibitors

Publications (1)

Publication NumberPublication Date
SG11201804098TAtrue SG11201804098TA (en)2018-06-28

Family

ID=57472109

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201804098TASG11201804098TA (en)2015-11-202016-11-18Purinones as ubiquitin-specific protease 1 inhibitors

Country Status (13)

CountryLink
US (4)US10189841B2 (en)
EP (2)EP3696181A1 (en)
JP (3)JP6964343B2 (en)
KR (1)KR102708936B1 (en)
CN (2)CN114702495A (en)
AU (3)AU2016356694B2 (en)
BR (1)BR112018010216B1 (en)
CA (1)CA3005353A1 (en)
IL (3)IL300788A (en)
MX (2)MX2021001186A (en)
RU (1)RU2750151C2 (en)
SG (1)SG11201804098TA (en)
WO (1)WO2017087837A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
MX2021001186A (en)2015-11-202022-10-11Forma Therapeutics IncPurinones as ubiquitin-specific protease 1 inhibitors.
EP3703669B1 (en)2017-11-012025-08-06Dana-Farber Cancer Institute, Inc.Usp1 or uaf1 inhibitors for use in treating cancer
WO2019189731A1 (en)2018-03-302019-10-03住友化学株式会社Heterocyclic compound and arthropod pest control composition containing same
KR102316234B1 (en)2018-07-262021-10-22주식회사 종근당1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
MA53275A (en)*2018-08-092021-09-15Valo Early Discovery Inc CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS
CN109503421B (en)*2018-11-202022-10-14黎明化工研究设计院有限责任公司Method for improving safety of azide amine fuel synthesis process
AU2019405925B2 (en)*2018-12-202025-07-03KSQ Therapeutics, Inc.Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
WO2020139988A1 (en)*2018-12-282020-07-02Forma Therapeutics, Inc.Compositions for inhibiting ubiquitin specific protease 1
WO2020240493A1 (en)*2019-05-312020-12-03Chong Kun Dang Pharmaceutical Corp.1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA3139026A1 (en)*2019-05-312020-12-03Chang Sik Lee1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN110759902B (en)*2019-11-012022-04-22海南一龄医疗产业发展有限公司SET8 lysine methyltransferase inhibitor and preparation method and application thereof
US20230183215A1 (en)*2020-05-212023-06-15Stemsynergy Therapeutics, Inc.Notch Inhibitors and Uses Thereof
EP4161494A4 (en)*2020-06-022024-07-17KSQ Therapeutics, Inc. NITROGEN-CONTAINING CONDENSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) INHIBITORS
KR102458689B1 (en)*2020-07-082022-10-25원광대학교산학협력단Piperidine compound and method for producing the same
KR102685058B1 (en)*2020-09-022024-07-15주식회사 종근당Novel Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
CN111926018B (en)*2020-09-042022-07-12首都医科大学附属北京儿童医院Application of substance for reducing USP1 expression in preparation of medicine for treating children T-line acute lymphoblastic leukemia
MX2023004937A (en)2020-10-302023-05-17Ksq Therapeutics IncSolid state forms of substituted pyrazolopyrimidines and uses thereof.
WO2022197892A1 (en)*2021-03-172022-09-22Tango Therapeutics, Inc.Purine derivatives as anticancer agents
WO2022199547A1 (en)*2021-03-222022-09-29成都赜灵生物医药科技有限公司7,9-dihydropurine derivative and pharmaceutical purpose thereof
CA3214040A1 (en)*2021-04-072022-10-13Forma Therapeutics, Inc.Inhibiting ubiquitin-specific protease 1 (usp1)
US20240226107A1 (en)*2021-04-092024-07-11Simcere Zaiming Pharmaceutical Co., Ltd.Ubiquitin-specific protease 1 (usp1) inhibitor
WO2023069959A1 (en)*2021-10-182023-04-27Dana-Farber Cancer Institute, Inc.Covalent egfr inhibitors and methods of use thereof
EP4429770A1 (en)*2021-11-102024-09-18Biogen MA Inc.Btk inhibitors
TW202327602A (en)*2021-11-122023-07-16香港商英科智能有限公司Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430050A4 (en)*2021-11-122025-09-24Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
JP2024543497A (en)*2021-11-122024-11-21インシリコ メディシン アイピー リミテッド Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
EP4472946A1 (en)*2022-02-032024-12-11Exelixis, Inc.Fused bicyclic heterocyclyl compounds as usp1 inhibitors
EP4516779A1 (en)*2022-04-292025-03-05Jiangsu Yahong Meditech Co., Ltd.Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
CN119731178A (en)*2022-06-232025-03-28福马治疗有限公司USP1 inhibitors and uses thereof
US20240092779A1 (en)*2022-06-292024-03-21Zentaur Therapeutics Usa Inc.Usp1 inhibitors and uses thereof
WO2024022266A1 (en)*2022-07-252024-02-01Guangdong Newopp Biopharmaceuticals Co., Ltd.Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (en)*2022-07-282024-02-01先声再明医药有限公司Heterocycle fused pyrimidine compound and use thereof
WO2024041634A1 (en)*2022-08-262024-02-29先声再明医药有限公司Tricyclic compound and use thereof
CN119698417A (en)*2022-09-092025-03-25正大天晴药业集团股份有限公司 Substituted purinone derivatives as ubiquitin-specific protease inhibitors
IL319492A (en)*2022-09-202025-05-01Chia Tai Tianqing Pharmaceutical Group Co LtdCarbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor
CN120092007A (en)*2022-10-092025-06-03海南先声再明医药股份有限公司 Heterocyclic pyrimidine compounds, pharmaceutical compositions and applications thereof
EP4605391A1 (en)2022-10-212025-08-27Exelixis, Inc.4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
WO2024153175A1 (en)2023-01-192024-07-25Laekna Therapeutics Shanghai Co., Ltd.Heteroaromatic compounds and their use as usp1 inhibitors
TW202509030A (en)2023-05-082025-03-01美商譚格醫療公司Compounds and methods of use
WO2024233665A1 (en)2023-05-082024-11-14Tango Therapeutics, Inc.Compounds and their use against cancer
WO2025010245A1 (en)2023-07-062025-01-09Exelixis, Inc.Fused pyrazole derivatives as usp1 inhibitors
CN116621846B (en)*2023-07-242023-10-17华润医药研究院(深圳)有限公司Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof
WO2025067259A1 (en)*2023-09-262025-04-03上海济煜医药科技有限公司Preparation method for nitrogen heterocyclic amine compound which acts as ubiquitin-specific protease 1 inhibitor, and application and use
WO2025102016A1 (en)2023-11-102025-05-15Vrise Therapeutics, Inc.Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en)2024-01-102025-07-17Vrise Therapeutics, Inc.Novel inhibitors of dna damage repair pathway
CN119707772B (en)*2024-12-232025-09-02浙江大学 A USP14 covalent inhibitor and its preparation method and application

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4440929A (en)1981-07-161984-04-03Usv Pharmaceutical CorporationImidazoquinoxaline compounds
DK476885D0 (en)1985-10-171985-10-17Ferrosan As HETEROCYCLIC RELATIONS AND PROCEDURES FOR PREPARING IT
US4859672A (en)1986-10-291989-08-22Rorer Pharmaceutical CorporationPyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
JPS63199347A (en)1987-02-141988-08-17Konica CorpHigh-sensitivity silver halide photographic sensitive material having improved sharpness
IL90315A0 (en)1988-06-011989-12-15Ferrosan AsImidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
DK626288D0 (en)1988-11-101988-11-10Ferrosan As CHEMICAL PROCESS FOR THE PREPARATION OF IMIDAZOQUINOXALINES AND INTERMEDIATES FOR USE IN THE PROCESS
FR2643903A1 (en)1989-03-031990-09-07Union Pharma Scient Appl NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS
DK588489D0 (en)1989-11-221989-11-22Ferrosan As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
CA2110942A1 (en)1991-06-141992-12-23Pharmacia & Upjohn Company LlcImidazo¬1,5-a|quinoxalines
AU4035893A (en)1991-12-171993-07-19Upjohn Company, The3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
EP0626966A1 (en)1992-02-191994-12-07PHARMACIA &amp; UPJOHN COMPANY3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
US6444656B1 (en)1992-12-232002-09-03Biochem Pharma, Inc.Antiviral phosphonate nucleotides
GB9226879D0 (en)1992-12-231993-02-17Iaf Biochem IntAnti-viral compounds
US5516774A (en)1993-07-291996-05-14American Cyanamid CompanyTricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5521173A (en)1995-01-171996-05-28American Home Products CorporationTricyclic benzazepine vasopressin antagonists
ZA973884B (en)1996-05-231998-11-06Du Pont Merck PharmaTetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
EP1043324B1 (en)1997-11-122004-06-16Mitsubishi Chemical CorporationPurine derivatives and medicine containing the same as the active ingredient
ZA9810490B (en)1997-12-031999-05-20Dainippon Pharmaceutical Co2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
TW572758B (en)*1997-12-222004-01-21Sumitomo PharmaType 2 helper T cell-selective immune response inhibitors comprising purine derivatives
CZ27399A3 (en)1999-01-262000-08-16Ústav Experimentální Botaniky Av ČrSubstituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments
JP3814125B2 (en)1999-06-022006-08-23大日本住友製薬株式会社 Pharmaceutical comprising 2-aryl-8-oxodihydropurine derivative
WO2001049688A1 (en)2000-01-072001-07-12Universitaire Instelling AntwerpenPurine derivatives, process for their preparation and use thereof
JP3675274B2 (en)2000-01-272005-07-27ダイソー株式会社 Method for producing 9- (2-hydroxyalkyl) purine derivative and 1- (2-hydroxyalkyl) pyrimidine derivative
US20020128264A1 (en)2000-07-072002-09-12Taylor Eve M.Methods for treatment of conditions affected by activity of multidrug transporters
EP1334104A2 (en)2000-07-072003-08-13Neotherapeutics, Inc.Methods for treatment of drug-induced peripheral neuropathy and related conditions
US20020040031A1 (en)2000-07-072002-04-04Glasky Michelle S.Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US20020040032A1 (en)2000-07-072002-04-04Glasky Michelle S.Methods for stimulation of synthesis of synaptophysin in the central nervous system
WO2002058736A2 (en)2000-12-122002-08-01Neotherapetics, Inc.Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6960595B2 (en)2001-03-232005-11-01Bristol-Myers Squibb Pharma Company5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US20020156277A1 (en)2001-04-202002-10-24Fick David B.Synthesis and methods of use of purine analogues and derivatives
JPWO2003068776A1 (en)2002-02-152005-06-02協和醗酵工業株式会社 [1,2,4] Triazolo [1,5-c] pyrimidine derivatives
CA2477741A1 (en)2002-02-282003-09-04Biota, Inc.Nucleotide mimics and their prodrugs
US7247621B2 (en)2002-04-302007-07-24Valeant Research & DevelopmentAntiviral phosphonate compounds and methods therefor
ES2270143T3 (en)2002-08-072007-04-01Novartis Ag ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF CONDITIONS MEDIATED BY ALDOSTERONE.
US7371857B2 (en)2002-08-082008-05-13Valeant Research & DevelopmentSynthesis for hydroxyalkylated heterocyclic bases
US20040166137A1 (en)2002-11-082004-08-26Lackey John WilliamHetero-substituted benzimidazole compounds and antiviral uses thereof
JP2004217582A (en)2003-01-162004-08-05Abbott Japan Co Ltd 9H-purine derivative
US20040180898A1 (en)2003-03-032004-09-16Bang-Chi ChenProcesses for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
AU2004255585A1 (en)2003-07-022005-01-20F. Hoffmann-La Roche Ag5-substituted quinazolinone derivatives
AU2004259736A1 (en)2003-07-232005-02-03WyethSulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands
US20050043239A1 (en)2003-08-142005-02-24Jason DouangpanyaMethods of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en)2003-08-142005-02-24Icos CorporationMethods of inhibiting leukocyte accumulation
CA2552664A1 (en)2004-01-082005-07-28Michigan State UniversityMethods for treating and preventing hypertension and hypertension-related disorders
AU2005214380A1 (en)2004-02-182005-09-01Astrazeneca AbFused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
CA2566436C (en)2004-05-132011-05-10Vanderbilt UniversityPhosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en)2004-05-252005-12-15Icos CorporationMethods for treating and/or preventing aberrant proliferation of hematopoietic cells
CA2569406A1 (en)2004-06-042005-12-22Icos CorporationMethods for treating mast cell disorders
WO2006044504A1 (en)2004-10-132006-04-27Merck & Co., Inc.Cgrp receptor antagonists
WO2006084281A1 (en)2005-02-042006-08-10Millennium Pharmaceuticals, Inc.Inhibitors of e1 activating enzymes
US20080287469A1 (en)2005-02-172008-11-20Diacovo Thomas GPhosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US7884109B2 (en)2005-04-052011-02-08Wyeth LlcPurine and imidazopyridine derivatives for immunosuppression
US20070021443A1 (en)2005-04-052007-01-25Ohlmeyer Michael JPurine and imidazopyridine derivatives for immunosuppression
US20090023723A1 (en)2005-09-212009-01-22Pharmacopeia Drug Discovery, Inc.Purinone derivatives for treating neurodegenerative diseases
DE102005062987A1 (en)2005-12-282007-07-05Grünenthal GmbH Substituted propiolic acid amides and their use for the preparation of medicaments
US7989459B2 (en)2006-02-172011-08-02Pharmacopeia, LlcPurinones and 1H-imidazopyridinones as PKC-theta inhibitors
AU2007267793A1 (en)2006-05-262007-12-06Novartis AgAldosterone synthase and/or 11beta-hydroxylase inhibitors
TW200817400A (en)2006-05-302008-04-16Elbion AgPyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2007149484A2 (en)2006-06-202007-12-27Dana-Farber Cancer InstituteInhibitors of usp1 deubiquitinating enzyme complex
US20100144738A1 (en)*2006-09-052010-06-10William BornmannInhibitors of c-met and uses thereof
JP5600004B2 (en)*2006-09-052014-10-01エモリー ユニバーシティー Tyrosine kinase inhibitors for the prevention or treatment of infection
WO2008045529A1 (en)2006-10-122008-04-17Serenex, Inc.Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
CA2666624C (en)*2006-10-192015-12-29Signal Pharmaceuticals, LlcHeteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US20080119496A1 (en)2006-11-162008-05-22Pharmacopeia Drug Discovery, Inc.7-Substituted Purine Derivatives for Immunosuppression
AU2006350748A1 (en)2006-11-162008-05-22Pharmacopeia, Llc7-substituted purine derivatives for immunosuppression
US7943617B2 (en)2006-11-272011-05-17Bristol-Myers Squibb CompanyHeterobicyclic compounds useful as kinase inhibitors
AR065784A1 (en)2007-03-202009-07-01Dainippon Sumitomo Pharma Co DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES.
JP2010522177A (en)2007-03-232010-07-01アムジエン・インコーポレーテツド Heterocyclic compounds and uses thereof
WO2008117796A1 (en)2007-03-282008-10-02Dainippon Sumitomo Pharma Co., Ltd.Novel mutilin derivatives
US20090182035A1 (en)2007-04-112009-07-16Alcon Research, Ltd.Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (en)2007-04-112009-10-29Alcon Res LtdUse of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis.
WO2008131501A2 (en)2007-04-272008-11-06Katholieke Universiteit LeuvenNew anti-viral nucleoside analogs
GB0708258D0 (en)2007-04-272007-06-06Katholleke Universiteit LeuvenNew anti-viral nulceoside analogs
WO2008143674A1 (en)2007-05-232008-11-27Pharmacopeia, Inc.Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2691857A1 (en)2007-06-262008-12-31Jorge AlonsoA regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
JP2009007273A (en)2007-06-272009-01-15Ajinomoto Co IncMethod for producing diaminopyrimidine compound
US20090118301A1 (en)2007-11-022009-05-07Arbor Vita CorporationCompositions and Methods for Treating Cancer
WO2009062059A2 (en)2007-11-082009-05-14Pharmacopeia, Inc.Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
EP2222661B1 (en)2007-11-202016-04-20Merck Sharp & Dohme Corp.Non-nucleoside reverse transcriptase inhibitors
JP2011505366A (en)2007-11-302011-02-24ワイス・エルエルシー Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10
WO2009068246A2 (en)2007-11-302009-06-04Elbion GmbhMethods of treating obesity and metabolic disorders
WO2009068320A1 (en)2007-11-302009-06-04Elbion GmbhAryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
JP2011509961A (en)2008-01-172011-03-31グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Substituted sulfonamide derivatives
EP2229394A1 (en)2008-01-172010-09-22Grünenthal GmbHSubstituted sulfonamide derivatives
EP2085398A1 (en)2008-02-012009-08-05Merz Pharma GmbH & Co. KGaAPyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en)2008-02-012009-08-19Merz Pharma GmbH & Co.KGaA6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2268280B1 (en)2008-03-212013-04-24Merck Sharp & Dohme Corp.Quinolizidinone M1 receptor positive allosteric modulators
CA2722308C (en)2008-04-152024-02-27Rfs Pharma, Llc.Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
WO2009137462A2 (en)2008-05-052009-11-12Envivo Pharmaceuticals, Inc.Methods for treating cognitive disorders using inhibitors of histone deacetylase
CN102131810B (en)2008-06-252014-02-26百时美施贵宝公司Diketone fused azolopiperidines and azolopiperazines as anti-HIV agents
CA2736522C (en)2008-09-092016-09-13Boehringer Ingelheim International GmbhAza-benzimidazolone chymase inhibitors
BRPI0918602B8 (en)2008-09-162021-05-25Benevolentai Cambridge Ltd health activity inhibitors, their use, and pharmaceutical formulation
CA2738429C (en)2008-09-262016-10-25Intellikine, Inc.Heterocyclic kinase inhibitors
US8835422B2 (en)2008-12-112014-09-16Cara Therapeutics, Inc.Substituted imidazoheterocycle derivatives
CN101824036A (en)2009-03-052010-09-08上海恒瑞医药有限公司Salt of tetrahydroimidazo [1,5-a] pyrazine derivative, preparation method and pharmaceutical application thereof
KR101675614B1 (en)2009-10-292016-11-11벡투라 리미티드N-containing heteroaryl derivatives as jak3 kinase inhibitors
JP2011136925A (en)2009-12-282011-07-14Dainippon Sumitomo Pharma Co LtdNitrogen-containing bicyclic compound
UA110697C2 (en)2010-02-032016-02-10Сігнал Фармасьютікалз, Елелсі USE OF TOR KINASE INHIBITORS FOR TREATMENT OF TUMOR DISEASES IN A PATIENT WITH A REDUCED PAMPK PROTEIN AND / OR AMPK ACTIVITY
WO2011137320A2 (en)2010-04-302011-11-03Dana-Farber Cancer Institute, Inc.Small molecule inhibitors of usp1 deubiquitinating enzyme activity
WO2011156889A1 (en)2010-06-142011-12-22Trt Pharma Inc.Novel modulators of nrf2 and uses thereof
EP2397482A1 (en)2010-06-152011-12-21Almirall, S.A.Heteroaryl imidazolone derivatives as jak inhibitors
JP2012012332A (en)2010-06-302012-01-19Dainippon Sumitomo Pharma Co LtdNew azaindole derivative
WO2012003576A1 (en)2010-07-062012-01-12Université de MontréalImidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en)2010-07-132012-01-19Edward RobertsPeptidomimetic galanin receptor modulators
CN102372716A (en)2010-08-092012-03-14江苏恒瑞医药股份有限公司Phthalazone derivative, its preparation method and application in medicine thereof
DE102010040233A1 (en)2010-09-032012-03-08Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
CN102485721B (en)2010-12-032015-12-09曹亚2,3-benzodiazine ketone compound replaced and uses thereof
TWI515187B (en)2010-12-162016-01-01健生科學愛爾蘭無限公司Indoles as respiratory syncytial virus antiviral agents
TWI501967B (en)2010-12-162015-10-01Janssen R&D IrelandAzaindoles as respiratory syncytial virus antiviral agents
TWI527814B (en)2010-12-162016-04-01健生科學愛爾蘭無限公司Azabenzimidazoles as respiratory syncytial virus antiviral agents
TWI541241B (en)2010-12-162016-07-11健生科學愛爾蘭無限公司Imidazopyridines as respiratory syncytial virus antiviral agents
WO2012102405A1 (en)2011-01-282012-08-02佐藤製薬株式会社Ring-fused compound
WO2012114252A1 (en)2011-02-212012-08-30Actelion Pharmaceuticals LtdNovel indole and pyrrolopyridine amides
CN105748484A (en)2011-03-262016-07-13福拉姆医药股份有限公司Methods of targeted treatment of frontotemporal lobar degeneration
WO2012136492A1 (en)2011-04-042012-10-11Siena Biotech S.P.A.Wnt pathway antagonists
WO2013025628A1 (en)2011-08-152013-02-21Ligand Pharmaceuticals IncorporatedJanus kinase inhibitor compounds and methods
WO2013033899A1 (en)2011-09-082013-03-14Merck Sharp & Dohme Corp.Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
IN2014CN02806A (en)2011-10-142015-07-03Bristol Myers Squibb Co
JP2014530861A (en)2011-10-192014-11-20シグナル ファーマシューティカルズ,エルエルシー Treatment of cancer with a TOR kinase inhibitor
US8501724B1 (en)2012-01-312013-08-06Pharmacyclics, Inc.Purinone compounds as kinase inhibitors
EP2817029B1 (en)2012-02-242019-07-10Signal Pharmaceuticals, LLCMethods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
WO2013134079A1 (en)2012-03-052013-09-12Amgen Inc.Oxazolidinone compounds and derivatives thereof
US9338896B2 (en)2012-07-252016-05-10Enthone, Inc.Adhesion promotion in printed circuit boards
US9566310B2 (en)2012-09-102017-02-14Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, RenoMethods of treating muscular dystrophy
WO2014043246A1 (en)2012-09-112014-03-20The Board Of Trustees Of The University Of IllinoisEnoyl reductase inhibitors with antibacterial activity
AU2013202768B2 (en)*2012-10-182015-11-05Signal Pharmaceuticals, LlcTreatment of cancer with TOR kinase inhibitors
AU2013370417A1 (en)2012-12-282015-07-16The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesInhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof
JP6024979B2 (en)2013-02-212016-11-16学校法人金沢工業大学 Flame retardant composition, flame retardant treatment method and flame retardant material using the same
CN103923085B (en)2013-02-252016-08-24苏州云轩医药科技有限公司Pyridine-heterocyclic compound with activity of hedgehog path antagonist and application thereof
JP2016516671A (en)2013-02-282016-06-09シグナル ファーマシューティカルズ,エルエルシー Treatment of cancer with TOR kinase inhibitors
US9187454B2 (en)2013-03-132015-11-17Boston Biomedical, Inc.Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
BR112015021549A2 (en)2013-03-132017-07-18Abbvie Inc pyridine kinase cdk9 inhibitors
TW201446768A (en)2013-03-152014-12-16Biogen Idec IncS1P and/or ATX modulating agents
EP2978425B1 (en)2013-03-272017-09-27Merck Sharp & Dohme Corp.Factor xia inhibitors
NZ754629A (en)2013-06-212021-07-30Zenith Epigenetics LtdNovel bicyclic bromodomain inhibitors
WO2015200677A2 (en)2014-06-252015-12-30Epizyme, Inc.Prmt5 inhibitors and uses thereof
CN106467538B (en)2015-08-142019-03-05沈阳中化农药化工研发有限公司A kind of substituted tetrahydro isoquinoline compound and purposes
MX2021001186A (en)2015-11-202022-10-11Forma Therapeutics IncPurinones as ubiquitin-specific protease 1 inhibitors.
CN107629071B (en)2016-07-192019-12-27上海勋和医药科技有限公司Substituted 2,4- (1H,3H) pyrimidinedione as PARP inhibitor and application thereof
CN107629057B (en)2016-07-192020-03-27上海勋和医药科技有限公司BET protein inhibitor and application thereof
US20180177784A1 (en)2016-12-222018-06-28Incyte CorporationHeterocyclic compounds as immunomodulators
AU2019405925B2 (en)2018-12-202025-07-03KSQ Therapeutics, Inc.Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
WO2020139988A1 (en)2018-12-282020-07-02Forma Therapeutics, Inc.Compositions for inhibiting ubiquitin specific protease 1

Also Published As

Publication numberPublication date
US10399980B2 (en)2019-09-03
CN114702495A (en)2022-07-05
KR20180095539A (en)2018-08-27
IL282103B2 (en)2023-08-01
AU2016356694A1 (en)2018-07-05
JP2021113224A (en)2021-08-05
EP3377493B1 (en)2020-04-08
US20200079776A1 (en)2020-03-12
CN108473495A (en)2018-08-31
IL259220A (en)2018-07-31
US12043623B2 (en)2024-07-23
EP3696181A1 (en)2020-08-19
KR102708936B1 (en)2024-09-25
JP7273886B2 (en)2023-05-15
MX2021001186A (en)2022-10-11
NZ743551A (en)2024-11-29
AU2023274204A1 (en)2023-12-21
AU2016356694B2 (en)2021-07-29
JP2019504821A (en)2019-02-21
JP6964343B2 (en)2021-11-10
CN108473495B (en)2022-04-12
RU2018121499A3 (en)2020-01-21
WO2017087837A1 (en)2017-05-26
US20220281869A1 (en)2022-09-08
JP2023011899A (en)2023-01-24
US10189841B2 (en)2019-01-29
EP3377493A1 (en)2018-09-26
MX2018005925A (en)2019-03-28
US11161848B2 (en)2021-11-02
BR112018010216B1 (en)2024-02-15
JP7650854B2 (en)2025-03-25
US20180339986A1 (en)2018-11-29
AU2021257988B2 (en)2023-12-21
IL259220B (en)2021-04-29
IL282103B1 (en)2023-04-01
US20170145012A1 (en)2017-05-25
IL300788A (en)2023-04-01
RU2750151C2 (en)2021-06-22
AU2021257988A1 (en)2021-12-09
IL282103A (en)2021-05-31
BR112018010216A2 (en)2018-11-21
MX379543B (en)2025-03-11
RU2018121499A (en)2019-12-20
CA3005353A1 (en)2017-05-26

Similar Documents

PublicationPublication DateTitle
SG11201804098TA (en)Purinones as ubiquitin-specific protease 1 inhibitors
SG11201804934PA (en)Novel Compounds
SG11201803920TA (en)Compounds and compositions useful for treating disorders related to ntrk
SG11201806544XA (en)Compounds and methods of treating rna-mediated diseases
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808878UA (en)Heterocyclic compounds as ret kinase inhibitors
SG11201909278SA (en)Fungicidal oxadiazoles
SG11201808990QA (en)Compositions for topical application of compounds
SG11201907451XA (en)Substituted imidazo-quinolines as nlrp3 modulators
SG11201805300QA (en)Heterocyclic compounds as immunomodulators
SG11201805044WA (en)Compounds useful as kinase inhibitors
SG11201811470PA (en)Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804373VA (en)Compositions and methods for immunooncology
SG11201804152RA (en)Heterocyclic compounds as immunomodulators
SG11201804443UA (en)Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201907356SA (en)Piperidine-substituted mnk inhibitors and methods related thereto
SG11201807827VA (en)Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201804589TA (en)Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201807540UA (en)Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201804704PA (en)Compositions and methods for decreasing tau expression
SG11201900665VA (en)Cannabis composition
SG11201909807TA (en)Methods of manufacturing of niraparib
SG11201808221QA (en)1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11202000333UA (en)Bicyclic ketone compounds and methods of use thereof

[8]ページ先頭

©2009-2025 Movatter.jp